Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.66 |
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MPL | P40238 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762257 | 0.87 | MPL (0.63) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL1765099 | 0.85 | ALDH1A1 (0.58) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL7236001 | 0.84 | ALDH1A1 (0.59) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL126685 | 0.84 | MPL (0.69) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL25735525 | 0.83 | ALDH1A1 (0.57) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL29085894 | 0.83 | RAB9A (0.65) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL17407200 | 0.81 | ALDH1A1 (0.58) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL25242184 | 0.80 | RAB9A (0.61) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL16345828 | 0.80 | RAB9A (0.57) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL10087446 | 0.80 | ALDH1A1 (0.61) | RAB9AALDH1A1NPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-8575178-B2 | Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-11-05 | — | — | US | disclosed |
| US-8575178-B2 | Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-11-05 | — | — | US | disclosed |
| US-8575178-B2 | Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2411397-B1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-01-12 | — | — | US | disclosed |
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-01-12 | — | — | US | disclosed |
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | RAB9A 2669/4885ALDH1A1 1565/4885NPC1 4059/4885 |
| US-20120010223-A1 | ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | RAB9A 2273/4885ALDH1A1 721/4885NPC1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.